

1. Sales January to June 2008 and 2007

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – June				
Pharmaceuticals Division	17,257	18,268	-6	+3
Roche Pharmaceuticals	10,938	11,367	-4	+2
Genentech	4,867	5,227	-7	+9
Chugai	1,452	1,674	-13	-11
Diagnostics Division	4,747	4,559	+4	+11
Roche Group	22,004	22,827	-4	+4

2. Sales January to June 2008 and 2007 excluding Pandemic Tamiflu\*

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – June				
Pharmaceuticals Division	17,162	17,062	+1	+9
Roche Pharmaceuticals	10,845	10,354	+5	+11
Genentech	4,867	5,227	-7	+9
Chugai	1,450	1,481	-2	0
Diagnostics Division	4,747	4,559	+4	+11
Roche Group	21,909	21,621	+1	+10

\* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

3. Quarterly local sales growth by Division in 2007 and 2008

	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007
<b>Pharmaceuticals Division</b>	+6	+5	+1	+5
Roche Pharmaceuticals	+1	+7	+1	+3
Genentech	+18	+6	+9	+9
Chugai	+8	-8	-23	+2
<b>Diagnostics Division</b>	+4	+8	+9	+13
<b>Roche Group</b>	+6	+6	+2	+7

4. Quarterly local sales growth by Division in 2007 and 2008 excluding Pandemic Tamiflu\*

	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007
<b>Pharmaceuticals Division</b>	+12	+11	+9	+10
Roche Pharmaceuticals	+10	+14	+11	+11
Genentech	+18	+6	+9	+9
Chugai	+4	+4	-2	+2
<b>Diagnostics Division</b>	+4	+8	+9	+13
<b>Roche Group</b>	+10	+10	+9	+10

\* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

5. Quarterly sales by Division in 2007 and 2008

CHF millions	Q2 2007	Q3 2007	Q4 2007	Q1 2008	Q2 2008
<b>Pharmaceuticals Division</b>	<b>9,126</b>	<b>8,856</b>	<b>9,659</b>	<b>8,568</b>	<b>8,689</b>
Roche Pharmaceuticals	5,665	5,425	6,178	5,498	5,440
Genentech	2,680	2,623	2,564	2,399	2,468
Chugai	781	808	917	671	781
<b>Diagnostics Division</b>	<b>2,343</b>	<b>2,264</b>	<b>2,527</b>	<b>2,287</b>	<b>2,460</b>
<b>Roche Group</b>	<b>11,469</b>	<b>11,120</b>	<b>12,186</b>	<b>10,855</b>	<b>11,149</b>

6. Quarterly sales by Division in 2007 and 2008 excluding Pandemic Tamiflu\*

CHF millions	Q2 2007	Q3 2007	Q4 2007	Q1 2008	Q2 2008
<b>Pharmaceuticals Division</b>	<b>8,666</b>	<b>8,664</b>	<b>9,201</b>	<b>8,523</b>	<b>8,639</b>
Roche Pharmaceuticals	5,203	5,314	5,736	5,455	5,390
Genentech	2,680	2,623	2,564	2,399	2,468
Chugai	783	727	901	669	781
<b>Diagnostics Division</b>	<b>2,343</b>	<b>2,264</b>	<b>2,527</b>	<b>2,287</b>	<b>2,460</b>
<b>Roche Group</b>	<b>11,009</b>	<b>10,928</b>	<b>11,728</b>	<b>10,810</b>	<b>11,099</b>

\* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

7. Top 20 Pharmaceuticals Division product sales<sup>1</sup> and local growth<sup>2</sup> in YTD June 2008: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	2,867	17%	1,381	13%	95	12%	1,391	21%
Herceptin	2,474	11%	712	6%	98	23%	1,664	14%
Avastin	2,351	36%	1,313	14%	71	2597%	967	78%
CellCept	1,010	13%	458	15%	19	17%	533	12%
NeoRecormon/Epogin	892	-14%	-	-	217	-23%	675	-10%
Pegasys	785	3%	176	-2%	41	71%	568	3%
Tarceva	587	28%	242	13%	20	-	325	34%
Xeloda	573	14%	186	10%	20	62%	367	14%
Bonviva/Boniva	507	51%	312	43%	-	-	195	68%
Lucentis	440	-2%	440	-2%	-	-	-	-
Tamiflu	327	-71%	264	-34%	16	-93%	47	-92%
Xenical	264	-16%	26	-40%	-	-	238	-12%
Valcyte/Cymevene	261	10%	116	8%	-	-	145	12%
Xolair	259	7%	259	7%	-	-	-	-
Pulmozyme	237	13%	126	12%	-	-	111	15%
Nutropin	195	-5%	188	-5%	-	-	7	-7%
Neutrogen	192	1%	-	-	192	1%	-	-
Rocephin	176	-9%	4	-62%	28	3%	144	-6%
Activase/TNKase	164	-7%	142	-9%	-	-	22	13%
Madopar	154	5%	-	-	9	5%	145	5%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined <sup>2</sup> versus YTD June 2007

8. Top 20 Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> in 2007 and 2008

	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007
MabThera/Rituxan	17%	12%	17%	16%
Herceptin	18%	14%	11%	12%
Avastin	45%	41%	35%	38%
CellCept	4%	16%	11%	16%
NeoRecormon/Epogin	-5%	-15%	-13%	-14%
Pegasys	7%	14%	-3%	10%
Tarceva	28%	24%	28%	27%
Xeloda	20%	22%	13%	14%
Bonviva/Boniva	62%	63%	56%	47%
Lucentis	31%	-9%	-5%	2%
Tamiflu	-60%	-46%	-64%	-86%
Xenical	-9%	-17%	-11%	-21%
Valcyte/Cymevene	9%	7%	9%	10%
Xolair	11%	2%	6%	7%
Pulmozyme	14%	13%	15%	11%
Nutropin	3%	-8%	-5%	-5%
Neutrogen	15%	14%	1%	1%
Rocephin	-2%	-4%	-4%	-13%
Activase/TNKase	6%	-2%	-3%	-11%
Madopar	5%	14%	0%	9%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

9. Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> US in 2007 and 2008

	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007
MabThera/Rituxan	14%	4%	14%	13%
Herceptin	6%	1%	9%	3%
Avastin	37%	23%	13%	15%
CellCept	-1%	17%	14%	15%
NeoRecormon/Epogin	-	-	-	-
Pegasys	-27%	-3%	-10%	5%
Tarceva	1%	5%	10%	17%
Xeloda	30%	19%	16%	5%
Bonviva/Boniva	27%	40%	47%	39%
Lucentis	31%	-9%	-5%	2%
Tamiflu	-71%	52%	83%	-87%
Xenical	-30%	-46%	-35%	-46%
Valcyte/Cymevene	4%	3%	11%	5%
Xolair	11%	2%	6%	7%
Pulmozyme	14%	10%	10%	14%
Nutropin	3%	-8%	-6%	-4%
Neutrogin	-	-	-	-
Rocephin	-13%	-32%	-34%	-85%
Activase/TNKase	6%	0%	-6%	-12%
Madopar	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

10. Pharmaceuticals Division quarterly local product sales growth Japan<sup>1</sup> in 2007 and 2008

	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007
MabThera/Rituxan	4%	2%	13%	11%
Herceptin	3%	0%	16%	29%
Avastin	-	-	-	1567%
CellCept	14%	18%	13%	21%
NeoRecormon/Epogin	-12%	-22%	-16%	-29%
Pegasys	34%	53%	98%	53%
Tarceva	-	-	-	-
Xeloda	11%	14%	48%	73%
Bonviva/Boniva	-	-	-	-
Lucentis	-	-	-	-
Tamiflu	48%	-58%	-93%	-78%
Xenical	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Xolair	-	-	-	-
Pulmozyme	-	-	-	-
Nutropin	-	-	-	-
Neutrogen	15%	14%	1%	1%
Rocephin	11%	-1%	9%	-2%
Activase/TNKase	-	-	-	-
Madopar	2%	3%	5%	5%

<sup>1</sup> Chugai

11. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World<sup>1</sup> in 2007 and 2008

	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007	Q2 2008 vs. Q2 2007
MabThera/Rituxan	23%	25%	21%	21%
Herceptin	26%	23%	12%	15%
Avastin	59%	80%	78%	78%
CellCept	9%	14%	8%	16%
NeoRecormon/Epogin	-2%	-11%	-13%	-7%
Pegasys	22%	20%	-4%	9%
Tarceva	68%	47%	40%	28%
Xeloda	15%	25%	11%	18%
Bonviva/Boniva	278%	160%	77%	61%
Lucentis	-	-	-	-
Tamiflu	-70%	-92%	-94%	-83%
Xenical	-5%	-11%	-7%	-17%
Valcyte/Cymevene	15%	11%	8%	16%
Xolair	-	-	-	-
Pulmozyme	14%	17%	22%	8%
Nutropin	-7%	-10%	-1%	-12%
Neutrogin	-	-	-	-
Rocephin	-4%	-3%	-3%	-9%
Activase/TNKase	1%	-16%	30%	1%
Madopar	5%	15%	0%	9%

<sup>1</sup> Roche Pharmaceuticals

12. Top 20 Pharmaceuticals Division quarterly product sales<sup>1</sup> in 2007 and 2008

CHF millions	Q2 2007	Q3 2007	Q4 2007	Q1 2008	Q2 2008
MabThera/Rituxan	1,395	1,380	1,432	1,407	1,460
Herceptin	1,214	1,209	1,261	1,225	1,249
Avastin	986	1,062	1,135	1,131	1,220
CellCept	503	485	548	487	523
NeoRecormon/Epogin	544	518	510	442	450
Pegasys	407	383	447	369	416
Tarceva	260	271	288	286	301
Xeloda	282	290	312	281	292
Bonviva/Boniva	204	230	283	241	266
Lucentis	261	239	228	215	225
Tamiflu	451	257	512	278	49
Xenical	176	151	142	136	128
Valcyte/Cymevene	137	137	144	125	136
Xolair	148	145	138	125	134
Pulmozyme	120	124	128	117	120
Nutropin	122	118	113	97	98
Neutrogen	99	100	110	95	97
Rocephin	104	95	100	91	85
Activase/TNKase	106	92	88	83	81
Madopar	77	76	83	74	80

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

13. Pharmaceuticals Division quarterly product sales<sup>1</sup> in US in 2007 and 2008

CHF millions	Q2 2007	Q3 2007	Q4 2007	Q1 2008	Q2 2008
MabThera/Rituxan	742	718	709	675	706
Herceptin	403	384	375	363	349
Avastin	689	718	693	642	671
CellCept	250	232	290	215	243
NeoRecormon/Epogin	-	-	-	-	-
Pegasys	107	75	111	81	95
Tarceva	125	121	129	119	123
Xeloda	109	114	123	89	97
Bonviva/Boniva	135	150	190	153	159
Lucentis	261	239	228	215	225
Tamiflu	319	98	398	234	30
Xenical	26	17	13	14	12
Valcyte/Cymevene	70	69	73	54	62
Xolair	148	145	138	125	134
Pulmozyme	67	68	67	61	65
Nutropin	118	115	108	94	94
Neutrogen	-	-	-	-	-
Rocephin	7	5	1	3	1
Activase/TNKase	94	80	76	71	71
Madopar	-	-	-	-	-

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

14. Pharmaceuticals Division quarterly product sales<sup>1</sup> in Japan in 2007 and 2008

CHF millions	Q2 2007	Q3 2007	Q4 2007	Q1 2008	Q2 2008
MabThera/Rituxan	48	49	55	43	52
Herceptin	45	39	44	42	56
Avastin	3	10	23	28	43
CellCept	9	9	10	8	11
NeoRecormon/Epogin	164	124	146	103	114
Pegasys	15	17	23	19	22
Tarceva	-	-	2	8	12
Xeloda	7	7	8	8	12
Bonviva/Boniva	-	-	-	-	-
Lucentis	-	-	-	-	-
Tamiflu	-2	81	69	16	0
Xenical	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Xolair	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Nutropin	-	-	-	-	-
Neutrogen	99	100	110	95	97
Rocephin	16	14	16	13	15
Activase/TNKase	-	-	-	-	-
Madopar	5	4	6	4	5

<sup>1</sup> Chugai

15. Pharmaceuticals Division quarterly product sales in Europe/Rest of World<sup>1</sup> in 2007 and 2008

CHF millions	Q2 2007	Q3 2007	Q4 2007	Q1 2008	Q2 2008
MabThera/Rituxan	605	613	668	689	702
Herceptin	766	786	842	820	844
Avastin	294	334	419	461	506
CellCept	244	244	248	264	269
NeoRecormon/Epogin	380	394	364	339	336
Pegasys	285	291	313	269	299
Tarceva	135	150	157	159	166
Xeloda	166	169	181	184	183
Bonviva/Boniva	69	80	93	88	107
Lucentis	-	-	-	-	-
Tamiflu	134	78	45	28	19
Xenical	150	134	129	122	116
Valcyte/Cymevene	67	68	71	71	74
Xolair	-	-	-	-	-
Pulmozyme	53	56	61	56	55
Nutropin	4	3	5	3	4
Neutrogen	-	-	-	-	-
Rocephin	81	76	83	75	69
Activase/TNKase	12	12	12	12	10
Madopar	72	72	77	70	75

<sup>1</sup> Roche Pharmaceuticals